MONTREAL, CANADA--(Marketwire - Jan 14, 2013) - Paladin Labs Inc. (PLB.TO), a leading Canadian specialty pharmaceutical company, announced today that all of the closing conditions have been fulfilled relating to the acquisition of a controlling stake in Ativa Pharma S.A. ("Ativa"), as mentioned in the press release on November 19, 2012. The transaction, as defined therein, has been completed with effect from January 1, 2013.
About Paladin Labs Inc.
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada''s leading specialty pharmaceutical companies. Paladin''s shares trade on the Toronto Stock Exchange under the symbol PLB. For more information about Paladin, please visit the Company''s web site at www.paladinlabs.com.
About Ativa Pharma S.A. de C.V.
Ativa Pharma is a start up specialty pharmaceutical company headquartered in Guadalajara, Mexico. It is involved in commercializing pharmaceuticals, medical devices and healthcare products for sale in the Mexican market. The company specializes in treatments in the areas of oncology, diabetes, urology, cardiovascular and pain management. Ativa has an infrastructure which provides its partners with registration, marketing, sales and pharmaceutical distribution services in Mexico.
Forward Looking Statements
This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The Company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the Company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the annual report as well as in the Company''s Annual Information Form for the year ended December 31, 2011. The Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law. For additional information on risks and uncertainties relating to these forward-looking statements, investors should consult the Company''s ongoing quarterly fillings, annual report and Annual Information Form and other fillings found on SEDAR at www.sedar.com.
- Investment & Company Information
- pharmaceutical company